Search

Displaying results 6561 - 6570 of 10000 in total
  1. Drug

    Rufinamide

    go.drugbank.com/drugs/DB06201
    Approved

    Clinical trials suggest its efficacy in the treatment of partial seizures. … Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy.

  2. Drug

    CR665

    go.drugbank.com/drugs/DB05155
    Experimental

    In addition, unlike currently marketed opioids, CR665 does not produce inhibition of intestinal transit (ileus), induce respiratory depression, or elicit signs of euphoria or addiction in animal models … In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound.

  3. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  4. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

  5. Drug

    Carbendazim

    go.drugbank.com/drugs/DB13009
    Investigational

    Carbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Thiabendazole

    go.drugbank.com/drugs/DB00730
    ApprovedVet approvedWithdrawn

    2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential.

  7. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.

  8. Drug

    Teniposide

    go.drugbank.com/drugs/DB00444
    ApprovedInvestigational

    Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. … This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.

    Synonyms: 4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)
  9. Drug

    KB002

    go.drugbank.com/drugs/DB05194
    Experimental

    KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.

  10. Drug

    Flutemetamol

    go.drugbank.com/drugs/DB15058
    Investigational

    Flutemetamol is under investigation in clinical trial NCT02353949 (Investigating the Clinical Consequences of Flutemetamol-PET-scanning).

    Categories: Compounds used in a research, industrial, or household setting